Brief: Epirus Biopharmaceuticals gives update on bow015 (infliximab biosimilar)
16/11/2015 11:05
Nov 16 (Reuters) - EPIRUS Biopharmaceuticals Inc EPRS.O : * Provides clinical program update on bow015 (infliximab biosimilar) * Says bow015 remains on track for 2017 global filing * Plans to initiate a global registration study for bow015 in the United States, Europe, other markets in Q1 2016 * Source text (http://bit.ly/1NzgJzS) * Further company coverage EPRS.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Epirus Biopharmaceuticals
See all newsBrief: Epirus Biopharmaceuticals entered settlement satisfaction amendment with Livzon Mabpharm
Brief: Jennison Associates dissolves passive stake in Epirus Biopharmaceuticals
Brief: Epirus Biopharmaceuticals enters term sheet with Zaklady Farmaceutyczne
Brief: Epirus Biopharmaceuticals announces reprioritization of pipeline
Brief: Epirus biopharmaceuticals files for non-timely 10-k - sec filing